Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
1970-01-01 08:00
Activist Fights Tick Up, Along With Settlements to Head Them Off
The first proxy season after a key US rule change was expected to rock the shareholder activism world.
1970-01-01 08:00
NATO Summit, Ukraine’s Arms Plan: Your Sunday US Briefing
Hello from Washington, where the dog days of summer have arrived and the unbearable humidity is ensuring DC
1970-01-01 08:00
How a Japanese Drugmaker Clinched Win Over Alzheimer’s
(This story was originally published Sept. 29. On Thursday, the US Food and Drug Administration granted full approval
1970-01-01 08:00
Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy
Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from US regulators, a move expected to widen access to
1970-01-01 08:00
Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug
Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to US regulators, paving the
1970-01-01 08:00
Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut
When Exondys 51 was approved to treat Duchenne muscular dystrophy, a deadly disease that puts kids in wheelchairs
1970-01-01 08:00